Harald Arnesen Selected Research

Fatty Acids (Saturated Fatty Acids)

9/2020	Very Long Chain Marine n-3 Polyunsaturated Fatty Acids in Atherothrombotic Heart Disease. A Brief Review, with a Focus on Metabolic Effects.
1/2016	Serum Fatty Acids, Traditional Risk Factors, and Comorbidity as Related to Myocardial Injury in an Elderly Population with Acute Myocardial Infarction.
10/2002	Serum non-esterified very long-chain PUFA are associated with markers of endothelial dysfunction.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Harald Arnesen Research Topics

Disease

53	Myocardial Infarction 04/2022 - 09/2002
35	ST Elevation Myocardial Infarction 04/2022 - 07/2005
27	Coronary Artery Disease (Coronary Atherosclerosis) 12/2022 - 10/2002
24	Atrial Fibrillation 01/2022 - 06/2007
21	Atherosclerosis 01/2022 - 01/2002
20	Thrombosis (Thrombus) 04/2022 - 02/2003
17	Infarction (Infarctions) 04/2022 - 10/2003
16	Coronary Disease (Coronary Heart Disease) 08/2020 - 01/2002
12	Heart Failure 04/2022 - 01/2009
12	Inflammation (Inflammations) 09/2020 - 11/2006
11	Stroke (Strokes) 01/2022 - 09/2002
11	Type 2 Diabetes Mellitus (MODY) 12/2021 - 03/2010
11	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2018 - 03/2009
10	Hemorrhage 01/2022 - 09/2002
8	Cardiovascular Diseases (Cardiovascular Disease) 12/2021 - 01/2004
6	Hypertension (High Blood Pressure) 09/2021 - 04/2007
6	Thrombophilia 12/2020 - 08/2012
5	Heart Diseases (Heart Disease) 09/2020 - 04/2012
5	Stable Angina 01/2017 - 11/2009
5	Acute Coronary Syndrome 04/2016 - 01/2010
4	Necrosis 12/2021 - 01/2013
3	Glucose Intolerance 10/2019 - 01/2009
3	Insulin Resistance 01/2019 - 04/2007
3	Hyperlipidemias (Hyperlipidemia) 01/2016 - 03/2005
3	Ischemia 03/2014 - 01/2010
2	Diabetes Mellitus 09/2021 - 12/2012
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2020 - 01/2020
2	Albuminuria 01/2019 - 01/2017
2	Vascular Diseases (Vascular Disease) 01/2019 - 01/2016

Drug/Important Bio-Agent (IBA)

15	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2017 - 09/2002
12	Biomarkers (Surrogate Marker)IBA 12/2021 - 05/2002
11	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 12/2021 - 03/2005
11	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 01/2009
9	Interleukin-18 (Interleukin 18)IBA 01/2019 - 03/2009
8	Troponin T (Troponin T1)IBA 01/2021 - 07/2014
8	Thromboplastin (Tissue Factor)IBA 01/2020 - 01/2003
8	Thrombin FDA Link 10/2018 - 02/2003
7	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2022 - 01/2005
7	Interleukin-6 (Interleukin 6)IBA 01/2021 - 11/2011
7	fibrin fragment D (D-dimer)IBA 10/2018 - 04/2006
7	AnticoagulantsIBA 04/2016 - 02/2003
7	candesartanIBA 01/2016 - 06/2007
7	Clopidogrel (Plavix)FDA Link 08/2012 - 12/2004
6	pro-brain natriuretic peptide (1-76)IBA 12/2022 - 01/2009
6	Matrix Metalloproteinases (MMPs)IBA 01/2022 - 11/2009
6	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 06/2008
6	Prothrombin (Factor II)IBA 10/2018 - 01/2010
6	N,N-dimethylarginine (asymmetric dimethylarginine)IBA 06/2012 - 02/2003
6	Warfarin (Coumadin)FDA LinkGeneric 04/2012 - 09/2002
5	Tissue Inhibitor of Metalloproteinase-1IBA 01/2022 - 01/2012
5	Proteins (Proteins, Gene)FDA Link 01/2021 - 12/2011
5	Insulin (Novolin)FDA Link 01/2020 - 04/2007
5	lipoprotein-associated coagulation inhibitor (TFPI)IBA 01/2018 - 01/2010
5	Chemokine CX3CL1IBA 01/2016 - 12/2012
5	Nitric Oxide Synthase (NO Synthase)IBA 02/2011 - 02/2003
4	Tissue Plasminogen Activator (Alteplase)FDA Link 04/2022 - 03/2005
4	Peroxidase (Myeloperoxidase)IBA 01/2020 - 12/2015
4	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2018 - 01/2009
4	Tissue Inhibitor of MetalloproteinasesIBA 01/2018 - 11/2009
4	Trinitrotoluene (TNT)IBA 05/2016 - 01/2014
4	CytokinesIBA 01/2016 - 03/2010
4	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 08/2012 - 12/2004
4	Arginine (L-Arginine)FDA Link 02/2011 - 02/2003
3	Plasminogen Activator Inhibitor 1IBA 04/2022 - 01/2008
3	omega-Chloroacetophenone (Mace)IBA 01/2022 - 01/2017
3	apixabanIBA 01/2022 - 04/2012
3	Eicosapentaenoic AcidIBA 01/2022 - 09/2020
3	Docosahexaenoic AcidsIBA 01/2022 - 01/2016
3	Phospholipids (Phosphatides)FDA LinkGeneric 09/2021 - 01/2004
3	Galectin 3 (LGALS3)IBA 08/2021 - 12/2015
3	AcidsIBA 01/2021 - 06/2008
3	Fatty Acids (Saturated Fatty Acids)IBA 09/2020 - 10/2002
3	Interleukin-8 (Interleukin 8)IBA 01/2020 - 01/2014
3	Basigin (Extracellular Matrix Metalloproteinase Inducer (EMMPRIN))IBA 01/2019 - 01/2014
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2019 - 10/2010
3	Troponin IIBA 09/2018 - 01/2016
3	Vitamin K FDA Link 04/2016 - 04/2012
3	Cytokine Receptor gp130IBA 01/2016 - 07/2013
3	C-Reactive ProteinIBA 01/2016 - 09/2012
3	Angiotensin II Type 1 Receptor BlockersIBA 01/2016 - 08/2007
3	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2016 - 01/2013
3	MB Form Creatine KinaseIBA 01/2016 - 12/2010
3	CD40 Ligand (CD40L)IBA 12/2015 - 09/2012
3	Tenecteplase FDA Link 08/2014 - 01/2010
3	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2013 - 11/2009
2	Plasminogen Activators (Plasminogen Activator)IBA 04/2022 - 01/2013
2	Enoxaparin (Lovenox)FDA LinkGeneric 01/2022 - 01/2010
2	AdiponectinIBA 12/2021 - 07/2010
2	Linoleic Acid (Linoleate)IBA 09/2021 - 12/2019
2	Corn Oil (Oil, Corn)IBA 01/2021 - 01/2006
2	InflammasomesIBA 01/2021 - 01/2019
2	Sirtuin 1IBA 08/2020 - 01/2019

Therapy/Procedure

25	Percutaneous Coronary Intervention 01/2017 - 04/2004
14	Therapeutics 01/2017 - 09/2002
9	Stem Cell Transplantation 09/2014 - 07/2005
8	Electric Countershock (Cardioversion) 01/2016 - 06/2007
4	Patient Readmission 10/2018 - 01/2016
4	Secondary Prevention 04/2012 - 09/2002
3	Stents 06/2010 - 11/2009
2	Glycemic Control 01/2020 - 01/2020